Mangoceuticals, Inc. (MGRX) Financial Statements
Industry: Misc Health & Allied Services (Other) (Services)
In fiscal 2025, Mangoceuticals reported revenue of $456,021, down 26.0% from $615,873 the year before. Net income was -$20.6M (a -4526.8% net margin), or -$2.17 per diluted share. Gross margin was 54.9% and operating margin was -3954.3%. Operating activities generated -$5.9M of cash. At fiscal year end, Mangoceuticals held $16.1M in total assets against $890,568 in total liabilities, including $1.5M of cash and equivalents.
Open the full interactive Mangoceuticals financials → Quarterly statements, key ratios, valuation history and price charts.
Mangoceuticals Key Stats
| Share Price | $0.37 |
|---|---|
| Market Cap | $6.4M |
| Revenue YoY Growth | -26.0% |
| 52-Week Range | $0.16 – $2.74 |
| Shares Outstanding | 17.1 million (basic, 2026 Q2) |
Mangoceuticals Income Statement
| FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|
| Revenue | $731,493 | $615,873 | $456,021 |
| Gross Profit | $431,501 | $379,964 | $250,386 |
| Operating Income | -$9.2M | -$8.0M | -$18.0M |
| Pre-Tax Income | -$9.2M | -$8.7M | -$20.6M |
| Income Tax | — | -$1,081 | -$461 |
| Net Income | -$9.2M | -$8.7M | -$20.6M |
| Diluted EPS | -$8.55 | -$4.84 | -$2.17 |
Mangoceuticals Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $84,246 | $94,360 | $67,864 | $68,757 |
| Net Income | -$7.6M | -$2.8M | -$3.4M | -$1.3M |
| Diluted EPS | -$0.69 | -$0.27 | -$0.22 | -$0.09 |
Mangoceuticals Balance Sheet
| FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|
| Cash & Equivalents | $739,006 | $58,653 | $1.5M |
| Current Assets | $818,460 | $75,595 | $1.5M |
| Total Assets | $1.1M | $15.4M | $16.1M |
| Current Liabilities | $211,078 | $1.4M | $890,568 |
| Total Liabilities | $276,039 | $1.4M | $890,568 |
| Shareholders' Equity | $774,754 | $13.9M | $15.2M |
Mangoceuticals Cash Flow Statement
| FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|
| Cash From Operations | -$7.0M | -$4.9M | -$5.9M |
| Cash From Investing | -$3,519 | $65,000 | — |
| Cash From Financing | $7.1M | $4.1M | $7.3M |
| Free Cash Flow | -$7.0M | -$4.9M | — |
Figures from Mangoceuticals' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Mangoceuticals financials page for every line item.
Mangoceuticals Company Profile
| Ticker | MGRX |
|---|---|
| Exchange | Nasdaq |
| Industry | Misc Health & Allied Services (Other) (Services) |
| Headquarters | Dallas, Texas |
| Incorporated in | Texas |
| Fiscal Year End | December 31 |
| SEC Filer Category | Emerging growth company |
| SEC CIK | 0001938046 |
Frequently Asked Questions
What was Mangoceuticals' revenue in fiscal 2025?
Mangoceuticals (MGRX) reported revenue of $456,021 for fiscal 2025.
What is Mangoceuticals' annual revenue history?
Mangoceuticals' annual revenue by fiscal year: 2023: $731,493; 2024: $615,873; 2025: $456,021.
What was Mangoceuticals' net income in fiscal 2025?
Mangoceuticals reported net income of -$20.6M for fiscal 2025.
What was Mangoceuticals' earnings per share (EPS) in fiscal 2025?
Mangoceuticals' diluted EPS was -$2.17 for fiscal 2025 (adjusted for any later stock splits).
What was Mangoceuticals' revenue last quarter?
In its most recent reported quarter (2026 Q2), Mangoceuticals reported revenue of $68,757.
How many shares of Mangoceuticals are outstanding?
Mangoceuticals reported a weighted average of 17.1 million basic shares outstanding in 2026 Q2.
What is Mangoceuticals' market cap?
Based on its latest closing price, Mangoceuticals (MGRX) has a market capitalization of about $6.4M.
When does Mangoceuticals' fiscal year end?
Mangoceuticals' fiscal year end, as registered with the SEC, is December 31.
Where is Mangoceuticals headquartered?
Mangoceuticals lists its business address in Dallas, Texas in its SEC filings.
Mangoceuticals Competitors & Similar Companies
See all 9 Misc Health & Allied Services (Other) (Services) companies →